Among patients with venous thromboembolism who have a transient provoking factor and enduring risk factors, the appropriate duration of anticoagulation is uncertain. Research findings from the HI-PRO trial are summarized in a new Quick Take video. nej.md/48s6HVq

#MedSky #Hematology

An opportunity to spend a year by the beautiful New Forest working with our delightful haematology team at University Hospital Southampton

www.nhsjobs.com/job/-v6978937

#hemesky

Practical article on acquired hemophilia! Need to be aware of it, even if not a hematologist, as abrupt onset of bleeding can rapidly become life threatening. No specialized lab support or pfVIII access? rfVIIa can work! A GOOD reason to page heme in the middle of the night. #hemesky #emedsky

10-15% of iTTP do not respond to rituximab. Targeting plasma cells can be promising.

In this study, durable responses to bortezomib were registered in 60% of multi-refractory iTTP patients, with mild-to-moderate toxicities.

www.jthjournal.org/article/S153...

#MedSky #HemeSky #TTP #bortezomib